The dysregulation of transfer RNA (tRNA) expression contributes to the diversity of proteomics, heterogeneity of cell populations, and instability of the genome, which may be related to human cancer susceptibility. However, the relationship between tRNA dysregulation and cancer susceptibility remains elusive because the landscape of cancer-associated tRNAs has not been portrayed yet. Furthermore, the molecular mechanisms of tRNAs involved in tumorigenesis and cancer progression have not been systematically understood. In this review, we detail current knowledge of cancer-related tRNAs and comprehensively summarize the basic characteristics and functions of these tRNAs, with a special focus on their role and involvement in human cancer. This review bridges the gap between tRNAs and cancer and broadens our understanding of their relationship, thus providing new insights and strategies to improve the potential clinical applications of tRNAs for cancer diagnosis and therapy.

**Keywords:** transfer RNA, human cancer, biomarker, tumorigenesis, therapy

**INTRODUCTION**

Cancer is one of the most complex diseases caused by multiple genetic disorders and cellular abnormalities. Its development and progression are regulated by multiple pathological processes (Bhawe and Roy, 2018), including environmental (Pan et al., 2018; Lewandowska et al., 2019), gender (Jara-Palomares et al., 2018), cultural (Tejeda et al., 2017; Lee, 2018), and lifestyle factors (Kerr et al., 2017; Jara-Palomares et al., 2018), as well as genetic mutations (Pak et al., 2015; Tejeda et al., 2017; Liew et al., 2019), epigenetic changes (Zhang and Huang, 2017; Porcellini et al., 2018; Liew et al., 2019), and abnormal signal transduction (Farooqi et al., 2018). Tremendous efforts have been made over the past decades with the aim of searching novel and more efficient tools in cancer therapy (Winn et al., 2016). However, cancer incidence and mortality remain high. Therefore, there is an urgent need to develop new strategies for early identification and more accurate diagnosis of cancer biomarkers for disease.

Recent studies on tRNAs have revealed the unexpected complexity of their structure and function (Schwartz et al., 2018). Besides participating in transcription and translation, tRNAs are also involved adaptive protein synthesis and can function as non-coding RNAs involving multiple
regulatory networks (Schimmel, 2018). Moreover, some small RNAs previously thought as miRNAs were actually tRNA-derived small RNA (tsRNAs). Compared with miRNAs, tRNAs, tsRNAs, and tRNA-derived fragments (tRFs) are more stable and richer in biological fluids in solid cancers and blood malignant tumors (Zhang et al., 2009; Li et al., 2012). High expression of plasma exosome tRNAs in patients with lung cancer (Balatti et al., 2017), chronic lymphocytic leukemia (Veneziano et al., 2019), and liver cancer (Zhu et al., 2019) indicate that plasma exosome tRNAs may be involved in cancer development. These findings provide evidence that tRNAs and their derivatives may be potential diagnostic and therapeutic molecular biomarkers of cancer (Schagaman et al., 2013; Dhabbi et al., 2014). In addition, mutation of the tRNA itself as well as supplementary proteins produced and modified by tRNA physiologically, are associated with cancer (Suzuki et al., 2011; Yao and Fox, 2013; Blanco and Frye, 2014). However, the exact molecular mechanisms by which tRNAs and tsRNAs are involved in cancer are unclear.

Moreover, in some cancers, the dysregulation of tRNAs can trigger the progression and proliferation of cancer cells by regulating transcription, translation, ribosome biogenesis and functioning as novel epigenetic factors. Although tRNAs and tsRNAs have been receiving increasing research attention, to date, there is no comprehensive summary of these findings, which would greatly be beneficial to future studies exploring tRNAs.

Herein, we detailed the current literature on tRNAs related to cancer. We comprehensively summarize the basic characteristics and functions of tRNAs, focusing on their involvement in various human cancers, particularly breast cancer, lung cancer, and melanoma. This review closes the gap between tRNAs and cancers and deepens our understanding of them, thereby providing new insights and strategies to guide researchers in further exploring the potential clinical applications of tRNAs in cancer diagnosis and treatment.

STRUCTURE AND BIOGENESIS OF TRNAS AND THEIR DERIVATIVES

tRNAs are fundamental biological molecules that complete the flow of genetic information from DNA to protein by reading the cognate codons in the mRNA (Kirchner and Ignatova, 2015). Mature tRNAs in human cells are derived from precursor tRNAs (pre-tRNAs) containing 5′ leader and 3′ trailer sequences and introns in the anticodon loop (Phizicky and Hopper, 2010; Raina and Ibbá, 2014). Mechanistically, pre-tRNAs are processed co- and post-transcriptionally to acquire their mature 5′ and 3′ ends, modified nucleosides, and the cloverleaf secondary structure, which contains four domains organized in unpaired and paired regions namely, acceptor arm, D arm, anticodon arm, and TγC arm.

Upon maturation, tRNAs obtains the L-shaped tertiary structure (Kim et al., 1974; Stout et al., 1976; Moras et al., 1980) by means of base build-up and non-Watson-Crick base pairing between the receptor and TγC arms, and with the D arm and the anti-coding arm (Madison et al., 1966) at the other end (Madison et al., 1966) (Figure 1). This structure allows tRNA to enter the ribosome and convert genetic information into polypeptides. During the translation process, mature tRNAs bind to adenosine covalently at the tail of the unchanging 3′CCA, acting as a connection and can be catalyzed by 20 different aminoacyl-tRNA synthases (Phizicky and Hopper, 2010). Generally, mature tRNAs are highly modified by tRNA-modifying enzymes, which play a vital role in obtaining 3D L-shaped structures and stability, translation start and extension factors, aminoacyl-tRNA synthases and ribosomes, and decoding efficiency and fidelity. Mature tRNAs add amino acids to the two-step reaction through aminoacyl-tRNA synthases, which are activated by ATP to form amino amp, and then add end adenosine to the tRNAs 3′ end (Figure 1). Then, the tRNAs charged with the amino acid interact with the enzyme machinery of the ribosome to decode mRNAs into proteins during translation (Figure 1). Meanwhile, tsRNAs are a class of non-coding small RNAs produced by mature tRNAs or pre-tRNAs at different sites that are widely present in prokaryotic and eukaryotic transcriptomes, and produced by mature tRNAs or pre-tRNAs at different sites. tsRNAs refers to specific nucleic acid enzymes such as Dicer and angiogenin, especially cells or specific cleavage of tRNAs under certain conditions, such as stress and hypoxia (Levitz et al., 1990; Thompson and Parker, 2009). There are two main types of tsRNAs: tRFs (Keam and Hutvagner, 2015) and the tRNA-derived, stress-induced RNAs (tiRNAs) (Saikia and Hatzoglou, 2015; Shigematsu and Kirino, 2017). tRFs are 14–30 nucleotides (nts) long, and tRFs can be further divided into four categories, namely tRF-5s, tRF-1s, i-tRF, and TRF-3s, depending on their position on tRNAs. tRF-5s come from the 5′ end of mature tRNAs without D-loop and have three subclasses: 1) tRF-5a about 14–16 bases, a cutting site before the D ring; 2) tRF-5b, containing 22–24 bases and cleavage site behind the D ring; and 3) tRF-5c, about 28–30 bases long, has cleavage site before the anticodon ring (Kumar et al., 2014). TRF-3s are rooted in the 3′ end of mature tRNAs and include a CCA parting without the L-loop. They are divided into two subclasses according to size. tRF-3a usually has a cleavage site before the T-ring, while the TRF-3 cleavage site is in the T-ring, and the TRF-3a is usually made up of 18 bases, while the tRF-3 is 22 bases (Kumar et al., 2016). tRF-1s, the third category, is produced at the 3′ end of the pre-tRNAs, and their 5′ ends begin just after the 3′ end of the mature tRNA sequence. Finally i-tRF comes mainly from the middle region of mature tRNAs (Lee et al., 2009).

tiRNAs (31–40 nts in length) are formed by cleaving the tRNA anticodon loop affected by sex hormones and their receptors (Rashad et al., 2020), and have two types: tRNA-5s and tRNA-3s (Anderson and Ivanov, 2014; Saikia and Hatzoglou, 2015). Angiogenin, the nuclease responsible for tiRNA formation, generally in the nucleus of cells but under certain conditions can enter the cytoplasm, belonging to the RNase A superfamily (Fu et al., 2009; Li and Hu, 2012). In response to stress, angiogenin is isolated by RNH1 (an angiogenin inhibitor), enters the cytoplasm from the nucleus, and cleaves tRNAs into tiRNA-5s and tiRNA-3s in the cytoplasm (Li and Hu, 2012) (Figure 1).
FIGURE 1 | Structure and pre-transcriptional changes in tRNAs. (A) Precursor tRNAs form mature tRNAs. (B) Aminoacyl-tRNA synthetase binds amino acids to its corresponding tRNAs by consuming energy. (C) tRNAs and ribosomes are involved in the translation process. (D) The process by which precursor tRNAs and mature tRNAs form four tsRNAs.
BIOLOGICAL ROLES AND FUNCTIONS OF TRNAS AND THEIR DERIVATIVES

The functions of tsRNAs in different pathways, such as increasing mRNA stability (Saikia and Hatzoglou, 2015; Shigematsu and Kirino, 2017), repressing translation (Kumar et al., 2014; Kumar et al., 2016), regulating ribosome biogenesis (Lee et al., 2009), functioning as novel epigenetic factors (Rashad et al., 2020), promoting RNA reverse transcription (Anderson and Ivanov, 2014), functioning as immune signaling factors (Fu et al., 2009), have recently emerged.

Regulation of mRNA Stability

As miRNAs, tRFs can reduce mRNA stability by mediating target gene deacetylation, thereby promoting mRNA degradation and instability. tRFs prioritizes the inhibition of ribosome proteins and translational initiation or elongation factors of mRNA translation through antisense pairing in Drosophila melanogaster (Karaiskos et al., 2015; Babiarz et al., 2008; Eichhorn et al., 2014). In human cells, The GW182 protein inhibits translation and promotes the degradation of target mRNAs, and the tRF-3 target mRNA pairs in the RNA-induced silencing complex associate with GW182 proteins, which means that tRFs can affect the function of RNA-induced silencing complex by regulating the stability of mRNA (Kuscu et al., 2018; Ren et al., 2019). Furthermore, in mature B lymphocytes, tRF-3s derived from tRNA\(^{\text{Gly-GCC}}\) (referred as CU1276) possess miRNA-like structure and function, thereby repressing mRNA transcripts by destabilizing mRNA, and can inhibit protein translation and the cleavage of a partially complementary target site, thereby
supressing proliferation (Shao et al., 2017a). Although some tRFs have similar functions to miRNAs, the formers have been expressed preferentially bind argonaute1, argonaute3, and argonaute4 to promote RNA-induced silencing complex formation and reduce the stability of mRNA, thus inhibiting mRNA translation, rather than binding argonaute2 like miRNA (Kumar et al., 2014; Haussecker et al., 2010) (Figure 2). In addition, tRF-2s blocks the interplay of Y-box binding protein 1 (YBX-1) and YBX-1 mRNAs by competitively binding to YBX-1. This reduces the stability of these mRNAs, which could subsequently reduce the genetic stability of human breast cancer cell metastasis (Goodarzi et al., 2015) (Figure 2). Moreover, some tRF-3s chimeras have been related to histone mRNAs and can thus affect mRNA stability by competing with stem-ring binding proteins in human cells (Kumar et al., 2014) (Figure 2). Although there is an increased understanding of some of the functions of tRFs in regulating mRNA stability, the functions of tRNA remain elusive.

**Downregulation of Translation**

Some studies have shown that tRNAs, mainly tRNA-5s, could decrease translation speed by 10–15% (Yamasaki et al., 2009). For instance, tRNA-5s from tRNA\textsuperscript{Ala} and tRNA\textsuperscript{Gys} form a G-quadruplex-like structure that selectively binds to eIF4G/ eIF4A in the translation of the starting complex, thereby inhibiting cap-dependent translation of cellular mRNAs rather than traditionally internal ribosome entry site mediated translation (Ivanov et al., 2011; Ivanov et al., 2014).

tRNAs can also selectively repress the housekeeping components’ translation under stress conditions, thereby reducing cell energy consumption without affecting the generation of pro-survival proteins (Li and Hu, 2012). These studies suggest that tRNAs are produced to regulate the translation process under stress conditions and are not intended to reduce the level of functional maturity tRNAs affecting mRNA function (Ivanov et al., 2011; Ivanov et al., 2014).

In addition, some researches have proved that tRFs plays a positive role in reducing protein translation behavior. For example, tRF-5s is supposedly involved in new mechanisms underlying the regulation of small RNA in human cell by repressing protein translation through conserved residues in tRNAs present in tRF-5s without the need for complementary target sites in mRNA (Sobala and Hutvagner, 2013). tRF-5s derived from tRNA\textsuperscript{Val-GAC} in *Halofexax volcanii* has been revealed to bind the small ribosomal subunit near the mRNA channel, leading to substitution in the initiation complex and thereby attenuating global translation both in vivo and in vitro (Gebetsberger et al., 2017).

**Regulation of Ribosome Biogenesis**

tRNAs have recently emerged as important regulators of ribosome biogenesis. Particularly, in the lower organism *Tetrahymena thermophila*, tRNAs are composition of the precursor ribosomal RNA splicing complex (Couvillion et al., 2012). In *Drosophila*, tRNAs restrain global translation by impeding ribosome biogenesis. Mechanistically, *Drosophila* argonaute2-bound tsRNAs preferentially inhibit the mRNA translation of ribosome proteins or translational initiation or elongation factors via an RNA-like pathway, thus attenuating overall translation (Couvillion et al., 2012; Dou et al., 2019). In addition, tRF-3s can recruit exonuclease Xrn2 and Tan1 protein to form compounds by specifically binding to the Twi12 protein, which cleaves and processes precursor ribosomal RNA to enhance ribosomal RNA synthesis in physiological conditions in *Tetrahymena* (Couvillion et al., 2012). In mammalian cells, tRF-3s from tRNA\textsuperscript{Ala-CAG} bind at least two ribosomal protein mRNAs to itself, such as ribosome proteins 28 and ribosome proteins 15, to promote translation (Kim et al., 2017) (Figure 2). However, the mechanism by which tsRNAs regulate ribosomal biogenesis in human remains to be explored.

**As Novel Epigenetic Factors**

Recent studies have unveiled that tsRNAs may function as epigenetic factors to regulate gene expression. Obese rat model under the control of a high-fat diet, increased levels of tRF\textsuperscript{Glu-TTC} directly targeted the transcription factors from the Kruppel-like factor (KLF) family, such as KLF9, KLF11, and KLF12, which are injected themselves into multiplication, apoptosis, differentiation and progress, and significantly suppressed their target mRNA expression, thus preventing the differentiation of preadipocytes (Shen et al., 2019) (Figure 2). Moreover, tRF\textsuperscript{Glu-TTC} suppressed adipogenesis by inhibiting lipids transcription factors’ expression (Shen et al., 2019). tRF-3s of different lengths can block reverse transcription and post-transcription silence by 18 and 22 nfs long respectively, thus silence the long terminal repeat reverse transcription transposer (Schorn et al., 2017). Furthermore, Dicer-like 1 processes tRF-5s and then integrates into argonaute1, which, like miRNA, regulates genomic stability by targeting the transcriptional elements in plant *Arabidopsis thaliana* (Martinez et al., 2017). Intriguingly, tsRNAs from high-fat diet male sperm injected into normal fertilized eggs of mature mouse sperm caused gene expression changes in the early embryo and triggered islet metabolic pathways independent of DNA methylation in CpG-enriched regions. This proves that tsRNAs may be a paternal epigenetic factor in the intergenerational inheritance of metabolic diseases affected by a mediated diet (Chen et al., 2016).

**Upregulation of RNA Reverse Transcription**

tRNAs can also act as an agonist for viral reverse transcription and promote the viral reverse transcription process in various ways. For example, tRF-3s can combine with the primer-binding site of human T cell leukemia virus type 1 RNA to initiate reverse transcription and promote viral synthesis of HIV-infected host cells (Ruggero et al., 2014). Meanwhile, the respiratory syncytial virus infection induces the angiotesinscuiting? tRNAs to produce tRNAs, thus triggering stress response in host cells. Respiratory syncytial virus uses host tRNAs as primers to promote its replication and improve the infection efficiency (Wang et al., 2013; Deng et al., 2015; Zhou et al., 2017).
Moreover, host cellular proteins can regulate retroviral replication by binding to tRNAs, thereby affecting all steps in the viral life cycle. In certain circumstances, aminoacyl-tRNA synthetases bind tRNAs and link them with their corresponding amino acids and cognate aminoacyl-tRNA synthetases to facilitate tRNA primer selection, thus promoting viral reverse transcription (Jin and Musier-Forsyth, 2019).

**Immune Regulation**

Studies have also revealed the potential role of tsRNAs as novel immune factors. tsRNAs are highly and stably expressed in hematopoietic and lymphatic organs and blood compared with other tissues (Dhabhi, 2015). This suggests that tsRNAs may participate in the immune process. In addition, when the body is in an acute inflammatory state, tsRNAs levels in the blood increase rapidly, particularly in the sera of mice and monkeys with acute and chronic hepatitis B and active hepatitis B virus infection, as well as chimpanzees with chronic viral hepatitis (Zhang et al., 2014; Selitsky et al., 2015). Likewise, tRF-5s derived from tRNA^Glu^ can lead to the inhibition of CD1A expression by compounding with PIWIL4 and PIWIL1, which was able to promote the maturation of monocytes into dendritic cells (Zhang et al., 2016) (Figure 3). Moreover, tsRNAs can also activate the immune response of Th1 and cytotoxic T lymphocyte by interacting directly with toll-like receptors (Wang et al., 2006) (Figure 3).

In addition, the specific nucleoside motifs of tsRNAs may be a structural determinant of innate immune recognition. For example, the interaction between the human tRNA^Ala^ stem loop and the D and T rings of tRNA^His^ may be epitopes of autoantibodies in the sera of patients with idiopathic inflammatory myopathy (Bunn and Mathews, 1987), and the anti-adenovirus infection-induced tRNAs fungal protective cell therapy (Alvarado-Vásquez et al., 2005). Finally, the major histocompatibility complex contains the largest tRNA gene cluster in human, which also coexist with immune-related functions are co-located. This may imply the role of tRNA in the immune system (Horton et al., 2004). These findings overall support the proposition that tRNAs may act as immune signaling molecules.

**Other Mechanisms of Action**

Both mitochondrial and cytosolic tRNAs have been shown to bind to cytochrome c. This binding inhibits the interaction between cytochrome c and apoptotic protease activating factor-1, thus blocking activating factor-1 oligomerization and caspase activation, which eventually preventing apoptosis (Mei et al., 2010). Another study revealed that under high osmotic pressure or stress, angiogenin-induced tRNAs can inhibit apoptotic formation and activity by binding cytochrome c to form a ribonucleoprotein complex (Saikia et al., 2014) (Figure 3). Moreover, tsRNAs can also regulate micro-organisms found in
**TABLE 1**  | Summary of human cancer-associated tRNAs and tsRNA.

| tRNAs and tsRNA | Function | Role | Cancer type | References |
|----------------|----------|------|-------------|------------|
| tRF<sup>Glu-YTC</sup> | Destabilization of YB-1 bound oncogenic transcripts then suppresses cell proliferation and cancer metastasis | Tumor suppressor | Breast cancer | Goodarzi et al. (2015) |
| tRF<sup>Asp-GTC</sup> | Promotes cell proliferation | Tumor suppressor | Prostate cancer | Lee et al. (2009) |
| tRF<sup>Gly-TCC</sup> | Sex hormone-dependent production, promote cell proliferation | Tumor suppressor | Breast cancer and prostate cancers | Honda et al. (2015) |
| tRF<sup>1001</sup> | Promotes cell proliferation and G0/G1 cell cycle progression, greatly upregulates in stage III and stages IV cases and relates with the development of stage | Tumor suppressor | Non-small cell lung cancer | Shao et al. (2017a) |
| tRF/miR-1280 | Inhibits cell proliferation and tumor growth through inhibiting Notch signaling pathway by targeting JAG2 | Tumor suppressor | Colorectal Cancer | Huang et al. (2017) |
| CUL1276/tRF-3018 | Associates with Argonaute proteins and represses endogenous RPA1, suppresses proliferation and modulates the molecular response to DNA damage | Tumor suppressor | B cell lymphoma | Maute et al. (2013) |
| tRF<sup>Ser-GCT</sup> | Unknown | Unknown | Breast cancer | Telonis et al. (2015) |
| tRF<sup>Ser</sup> | Cleavage of tRNAs during stress | Unknown | Hepatocellular cancer | Fu et al. (2009) |
| tRF<sup>Lys-GT</sup> | Combine with AGO2 and target HIV primers with binding sites | Unknown | Cervical cancer | Yeung et al. (2009) |
| tRF<sup>Leu-CAG</sup> | Associates with AGO2 and down-regulate target genes by transcript cleavage | Unknown | B cell lymphoma | Li et al. (2012) |
| tRF<sup>Nia</sup> | Inhibits protein synthesis and triggers the phospho-eIF2α independent assembly of stress granules | Promoting tumor | Osteosarcoma | Ivanov et al. (2011) |
| tRF<sup>Cys</sup> | Induces the assembly of cytoprotective stress granules in response to DNA damage | Unknown | Osteosarcoma | Emara et al. (2010) |
| tRF<sup>His</sup> | Inhibits the process of protein translation without the need for complementary target sites in the miRNA | Tumor suppressor | Cervical cancer | (2013) |
| cand14 | Primarily associates with AGO3 and AGO4, RNA silencing by targeting luciferase reporter gene | Unknown | Kidney and colorectal cancer | Haussecker et al. (2010) |
| cand45 | Associates with response to the treatment of DNA methyltransferase inhibitors | Unknown | MDS | Guo et al. (2015) |
| Multiple tRFs | Overexpresses in metastatic tissues, potential diagnostic and prognostic biomarkers | Unknown | Prostate cancer | Martens-Uzunova et al. (2012) |
| tRF<sup>544</sup> | High expression ratio of tRF-315/tRF-544 predict poor PFS | Unknown | Prostate cancer | Ovedy et al. (2016b) |
| tRF<sup>315</sup> | Greater downregulation in advances and less differentiates in ccRCC tissues | Tumor suppressor | Clear cell renal cell carcinoma | Nentiedt et al. (2016), Zhao et al. (2018) |
| tRF<sup>03357</sup> | Promotes cell proliferation, migration, and invasion | Tumor suppressor | Lung cancer, breast cancer | Balatti et al. (2017) |
| tRF<sup>315</sup> | Tumor suppressor | Lung cancer, CLL | Pekarsky et al. (2016) |
| tRNA<sup>1236-3p</sup> | Suppresses the proliferation, migration, and invasion capacity of cancer cells | Tumor suppressor | Hepatocellular cancer, ovarian cancer, bladder cancer, gastric cancer | An et al. (2019) |
| tRF-03357 | Promotes cell proliferation, migration, and invasion | Tumor suppressor | High-grade serous ovarian cancer | Zhang et al. (2019b) |
| tRNA<sup>16</sup> | Promotes cell proliferation and transformation | Tumor promoter | ER+ breast Cancer | Fang et al. (2017) |
| tRNA<sup>19</sup> | Initiated tumorigenesis | Tumor promoter | Triple-negative breast cancer | Khattar et al. (2016) |
| tRNA<sup>14</sup> | Increases protein synthesis and proliferative ability of cancer cells | Tumor promoter | Her2(erbB2)-positive breast | Kwon et al. (2018) |
| tRNA<sup>10</sup> | Involved in the carcinogenesis of breast cancer | Tumor promoter | Breast cancer | Meng et al. (2016) |
| tRNA<sup>4</sup> | Promotes metastasis and invasion | Tumor promoter | Breast cancer | Goodarzi et al. (2016) |
| methionine tRNA | Advances cancer cell migration, invasiveness, and lung colonization capacity | Tumor promoter | Melanoma | Birch et al. (2016) |

(Continued on following page)
In the oral cavity, the presence of *Fusobacterium nucleatum* triggers the release of tsRNAs, which may inhibit the growth of the former by interfering with the biosynthesis of bacterial proteins (He et al., 2018). At present, studies exploring the function of tRNAs are only emerging. Future researches are expected to reveal the further regulatory role of tRNAs and tsRNAs in biological functions.

### TRNAS AND TSRNAS IN HUMAN CANCER

tRNAs dysregulation have been detected in a variety of cancers, including breast cancer (Fang et al., 2017), lung cancer (Liu et al., 2009), melanoma (Phizicky and Hopper, 2010), prostate cancer (Olvedy et al., 2016a), and tRNA has been revealed to be regulated by oncogenes and tumor-suppressor genes. Particularly, oncogenes Ras (Wang et al., 1997) and c-myc (Gomez-Roman et al., 2003) can promote the expression of RNA polymerase III, whereas suppressor genes Rb (White et al., 1996) and p53 (Crighton et al., 2003) can inhibit its transcription. This leads to a serious imbalance of tRNA expression in cancers. Abnormally expressed tRNA can also promote cell proliferation and inhibit cell apoptosis, thus promoting tumor progression (Pavon-Eternod et al., 2013; Kwon et al., 2018).

In addition, the tRNA modification system can initiate tumorigenesis by directly affecting cellular processes associated with characteristic cancer cell phenotypes, such as increased proliferation, metastasis potential, and stem cell...
survival (Endres et al., 2019). Further, the tRNA modification system is also a key component of carcinogenic signaling pathways (Endres et al., 2019). In various cancers, the tRNA modifying enzyme increases the modification of a specific tRNA, thereby altering the preference of the tRNA codon. This results in increased levels of proteins corresponding to these mRNAs was found to be rich in a particular subset of the new “preferred” codons (Novoa et al., 2012; Novoa and Ribas De Pouplana, 2012).

Mutations in mitochondrial tRNA (mt-tRNA) have been confirmed that increased tumorigenic relates to the invasive phenotypes (Amuthan et al., 2001). These mutations can seriously affect the tertiary structure of mt-tRNAs, thus severely damaging the synthesis of mitochondrial proteins (Grzybowska-Szatkowska and Slaska, 2012). At present, the involvement of mt-tRNA mutations in the carcinogenesis of breast and lung cancers has been confirmed (Lu et al., 2009; Meng et al., 2016).

FIGURE 5 | Roles of tRNAs and tsRNAs in breast cancer.
Several studies have also reported that tsRNAs, a derivative of tRNA, is dysregulated in a variety of cancers and may play a carcinogenic or anti-cancer role (Pekarsky et al., 2016; Balatti et al., 2017). In breast cancer, many studies have shown that cancer genes can regulate the expression of tsRNAs, which may also be a key effector molecule in cancer gene regulation (Balatti et al., 2017).

While current knowledge of tRNAs and tsRNAs in cancer is still in its infancy, their potential applications in the improvement of fresh biomarkers and original healthful strategies for the diagnosis, monitoring, predicting, and treating cancer cannot be understated. We have summarized the recent literature on the functions and mechanisms of cancer-associated tRNAs in Table 1 (Figure 4).

**Breast Cancer**

Different factors can induce the abnormal expression of tRNAs in breast cancer, thereby promoting tumor progression. For example, the stimulation of ethanol activates c-Jun N-terminal kinase 1, which promotes the proliferation of Brf1 and ERα. Subsequently, the interaction between Brf1 and ERα upregulates Pol III gene transcription to enhance the production of tRNA, ultimately leading to the development of breast cancer. However, tamoxifen can hold in the incident of breast cancer by containing ERα, thereby increasing the translation of the oncogenic LEF-1 mRNA (Fang et al., 2017) (Figure 5). Similarly, the TATA box-binding protein human Mafl and the oncogene Ras can promote the transcription of tRNAs by targeting RNA pol III, particularly the Brf1 subunit of TFIII B factor, thereby promoting tumor progression (Wang et al., 1997; Shen et al., 1998; Rollins et al., 2007; Johnson et al., 2008).

Enzymes catalyzing tRNA modifications play significant roles in the biological processes in breast cancer (Towns and Begley, 2012; Frye and Watt, 2006; Delaunay et al., 2016). In human, the overexpression of the U34-modifying enzymes Elp3 and Ctu1/2 directly promoted the translation of the oncogene DEK by catalyzing the mc5's-U34 tRNA modification. Increased DEK can then bind the LEF1 internal ribosome entry site sequence, thereby increasing the translation of the oncogenic LEF-1 mRNA and promoting the invasion and metastasis of breast cancer cells (Delaunay et al., 2016) (Figure 5). Furthermore, the high expression of tRNAArg-GCC and tRNAGlu-UUC in breast cancer can promote the invasion and metastasis of cancer cells by directly upregulating the expression of EXOSC2 and enhancing that of GRIPAP1 (Goodarzi et al., 2016).

In a study cohort of Polish women with breast cancer, the tertiary structure of mt-tRNAs was affected by genetic mutation, resulting in the severe impairment of the mitochondrial protein synthesis, and thus affecting cell proliferation (Grzybowska-Szatkowska and Slaska, 2012). Further, mutations in mt-tRNAs are participated in the carcinogenesis of breast cancer, such as mt-tRNAAsp (Meng et al., 2016), but the specific mechanism of mt-tRNA mutation in cancer is unknown.

Similarly, tiRNAs are abnormally expressed in breast cancer and are involved in tumorigenesis (Goodarzi et al., 2015; Honda et al., 2015; Balatti et al., 2017). Decreased abundances of 26 specific circulatory tiRNAs from the tRNAAsp, tRNAAsp, and tRNAlys heterogenous receptors was observed in ER-positive breast cancer (Dhahbi et al., 2014). The same study have suggested that inflammatory breast cancer is associated with an increase in tiRNAAsp (Dhahbi et al., 2014). Some tiRNAs, such as tiRNAAsp, and tiRNAlys, are significantly overexpressed in breast cancer, and the knockout of tiRNA-5s can inhibit tumor proliferation (Honda et al., 2015). These findings provide sufficient evidence of the involvement of abnormal tiRNAs expression in the course of breast cancer.

The connection of tsRNAs in breast cancer progression has also been confirmed by several studies. First, the anomalous demonstration of tiRNAs has been sighted at some stages of the carcinogenesis process [19]. The downregulation of tiRNAVal-5 in the serum is positively associated with lymph node metastasis and cancer stage progression, whereas its overexpression inhibits malignant cell activity (Mo et al., 2019). Meanwhile, the expression of tRF-3s are strongly downregulated in invasive advanced breast cancer, whereas that of tRF-1s were raised in an advanced cancer cell, thus suggesting that tRF-3s and tRF-1s may be related to advanced pathological changes in cancer (Balatti et al., 2017). Second, tsRNAs can regulate breast cancer progression by affecting gene transcription. For example, tRFs from tRNAGlu, tRNAAsp, tRNAAsp, and tRNAlys contredit with YB-1 for the transcription of endogenous cancer genes, thereby undermining the stability of transcriptions of proteo-oncogene and reducing their expression. This subsequently inhibits breast cancer progression (Goodarzi et al., 2015). Similarly, in breast cancer cells, tRFs derived from tRNAAsp, tRNAAsp, tRNAAsp, and tRNAGlu can inhibit tumor progression by displacing the 3'-UTRs of multiple oncogenic transcripts from the RNA-binding protein YBX-1, thus reducing their stability (Goodarzi et al., 2015). Another study showed that tiRNAVal-5 leads to the inhibition of c-myc and cyclinD1 by downregulating the FZD3-Wnt/β-catenin axis, which inhibits the progression of breast cancer (Mo et al., 2019) (Figure 5). Third, the impairment of the tiRNAs production also affect cancer progression. estrogen and its receptors promote the angiogenin cutting mature tRNA anticodon ring, thus producing large amounts of tiRNAs in ER-positive breast cancer. This accumulation makes for cells proliferating, which may promote tumor occurrence and tumor growth (Honda et al., 2015). Meanwhile, in a hypoxic environment, angiogenin induces the production of tsRNAs, and tsRNAs then interact with interleukin-6 to promote the phosphorylation of signal transducers and activators of transcription proteins. This promotes the transcription of the hypoxia inducible factor-1α, as well as those of multidrug-resistant genes and glycolytic proteins, ultimately leading to cytochemical resistance (Cui et al., 2019) (Figure 5). These studies suggest the varied functions of tsRNAs in cancer pathogenesis.

**Lung Cancer**

mt-tRNA gene mutations have been found to promote the development of lung cancer (Lu et al., 2009). These mutations damage the secondary structure of tRNAs, thereby affecting post-transcriptional modifications and aminoacylation, which can change the specificity, stability, or affinity of tRNAs (Brulé et al., 2011).
et al., 1998). Further, these mutations caused a decrease in mitochondrial protein synthesis and the cellular inability to reach the respiratory phenotypes and ATP thresholds required by normal cells to promote lung cancer (Lu et al., 2009) (Figure 6). The drug BC-Li-0186 when combined with leucyl-tRNA synthetase inhibited its activity, reduced the abundance of tRNA-carrying leucine, and prevented leucyl-tRNA synthetase mediated the non-classical mammalian target of rapamycin complex 1. This ultimately restrains the development of non-small cell lung cancer (Kim et al., 2019) (Figure 6).

tsRNAs have also been associated with lung cancer development through its regulation of the biological behavior of cells. For instance, miR-4521, acts as an inhibitor in CLL, has been revealed to be a tsRNA (ts-4521), which is lowered and mutated genes in lung cancer. Meanwhile, a reduction in ts-4521 has been shown to support tumor movement by the cell proliferation-related pathways’ activation and inhibiting apoptosis-related pathways in cancer cells (Phizicky and Hopper, 2010; Pekarsky et al., 2016). In addition, tsRNAs can regulate the demonstration of oncogenes. tRF-Leu-CAG is highly expressed in non-small cell lung cancer tissues, promoting tumor cell proliferation and cell cycle progression by upregulating the oncogene AURKA (Shao et al., 2017b) (Figure 6). However, how to mediate other signaling pathways through AURKA remains unclear.

**Melanoma**

Melanoma is highly malignant and accounts for the majority of skin tumor deaths. The roles of tRNAs and tsRNAs in its melanoma have also been investigated. The overexpression of the promoter methionine tRNA gene promoted tumor growth and angiogenesis in mouse melanoma cells, as well as an increase in cancer cell migration, invasion, and lung colonization, thereby resulting in increased metastasis potential (Phizicky and Hopper, 2010; Clarke et al., 2016). Its upregulation in cancer-associated fibroblasts accelerated the secretion of stromal cells, especially type-II collagen, thus facilitating tumor growth and metastasis (Phizicky and Hopper, 2010) (Figure 7).

In a recent study, the accurate translation of hypoxia inducible factor 1α mRNA in melanoma requires the participation of 34 uridine tRNA-modifying enzymes to adapt to a metabolic environment that is not conducive to growth conditions. The particular translation reprogramming of which relies partly on mTORC2-mediated enzymatic phosphorylation to modify the anti-codon of tRNA. Further, enhanced codon dependence on hypoxia inducible factor 1α...
translation can promote glycolytic metabolism and the proliferation of melanoma cells (Mcmahon and Ruggero, 2018) (Figure 7). However, the specific regulatory mechanism of tRNAs in melanoma needs further validation, whereas the role of tsRNAs in melanoma has yet to be studied.

Other Cancers

tRNAs and tsRNAs have also been implicated in the biological processes of liver (Selitsky et al., 2015) and prostate cancers (Olvedy et al., 2016b). In liver cancer, tsRNAs tRNA^{Val-TAC-3}, tRNA^{Gly-TCC-5}, tRNA^{Val-AAC-5}, and tRNA^{Glu-CTC-5} were significantly increased in plasma exosomes (Selitsky et al., 2015) (Figure 8). Meanwhile, the expression of tiRNA^{Arg-CCT-5}, tiRNA^{Glu-CTC-5}, tiRNA^{Leu-CAG-5}, and tiRNA^{Lys-TTT-5} was downregulated in clear-cell renal-cell carcinoma, suggesting a potential role as a tumor suppressor (Zhao et al., 2018). Moreover, the relative abundance of tiRNA^{Gly} is 50–60% lower in hepatitis B virus and Hepatitis C virus-related cancers than normal liver tissue (Selitsky et al., 2015). These findings suggest that tRNAs and tsRNAs may have opposite effects in liver cancer and clear-cell renal-cell carcinoma and may thus be used as new diagnostic biomarkers.

tsRNA (CU1276) modulated DNA damage response and suppressed cell proliferation via the inhibition of RPA1, which is an endogenous single-stranded DNA binding protein, in B cell lymphoma cells (Maute et al., 2013) (Figure 8). Meanwhile, tRNA^{Leu} and pre-miRNA derived from tRF/miR-1280, can suppress the growth and transfer of colorectal cancer by inhibiting Notch signaling pathways. Particularly, tRF/miR-1280 can target the Notch ligand jagged 2 (JAG2) to repress Notch signaling pathways, which in turn inhibits the cancer stem cell phenotypes by inhibiting direct transcription of Gata1/3 and miR200b genes, thus inhibiting tumorigenesis and metastasis (Huang et al., 2017) (Figure 8).

In high-grade serous ovarian cancer, upregulated tRFs can promote protein phosphorylation, transcription, cell migration, cancer pathways, MAPK, and Wnt signaling pathways, as well as regulating HMBOX1 to attack human ovarian cancer cells (Zhang et al., 2019a). This proves that tRFs play a role as a regulatory factor for cancer development in serous ovarian cancer (Figure 8). In prostate cancer, 589 differentially expressed tRFs have been detected, suggesting its potential as a biomarker (Olvedy et al., 2016b). Similarly, tRF-1001 from tRNA^{Ser} was eminently expressed in prostate cancer, whereas its knockdown suppressed DNA biosynthesis and cell proliferation (Anderson and Ivanov, 2014).

CLINICAL APPLICATION OF TRNAS AND TSRNAS IN CANCER

Although tsRNAs and tRNAs function in the human body are still in the exploratory stage, the potential it has shown as a cancer marker is not to be underestimated. Next, we will discuss its role in clinical diagnosis and treatment.
As a Diagnostic Biological Marker
Cancer is the most dangerous disease known. In many cases, patients with cancer are often unaware of their early stages, and when clinical symptoms appear, the cancer is in its late stages. Finding reliable and sensitive diagnostic molecular markers is something researchers have been struggling to find. Recently, the function of tRNAs and tsRNAs in the human body has gradually received clinical attention and shown great molecular marker potential.

Previous studies have shown that tsRNAs can be detected in serum and urine stabilized (Romaine et al., 2015; Santos et al., 2019). Now, with the continuous development of high-throughput sequencing technology, different types of tsRNAs are constantly detected and isolated in body fluids, and their functions are gradually reflected. For example, there are differences in abundance between prostate cancer and renal transparent cell carcinoma and tsRNAs in normal prostate tissue (Hayes et al., 2014; Zhao et al., 2018). Subsequently, many studies have found tRNAs and tsRNAs disorders may be related to the regulation of tumor genes and tumor suppressor genes, while the abnormal expression of tRNAs and tsRNAs can promote cell proliferation and inhibit cell apoptosis, further promoting cancer progression (Fang et al., 2017). Meanwhile, many studies have shown that cancer genes can regulate the expression of tsRNAs and tsRNAs may also be a key effector molecule of cancer gene regulation (Zhu et al., 2019). On the other hand, in hepatocellular carcinoma, tsRNAs tRNAVal-TAC-3, tRNAVal-Glu-CTC-5, tRNAVal-AAC-5, and tRNAValGlu-CTC-5 are significantly elevated in plasma exosomes, which may play a transcriptional role (Selitsky et al., 2015). These characteristics are sufficient to demonstrate the great potential of tsRNAs to become a biomarker of tumors. But there is still less research on tsRNAs, and hopefully more people will look to it in the future so that tsRNAs can really play its clinical role and contribute to the cause of human medicine.

The Role of Targeted Therapy
tRNAs and tsRNAs, as small molecular markers related to tumor, may also play a role in molecular targeted therapy to suggest local therapeutic targets. For example, mt-tRNA mutations in lung cancer inhibit the development of NSCLC by leucyl-tRNA synthase mediated rapamycin complex 1 as a non-classical mammalian target (Kim et al., 2019). In high-grade serous ovarian cancer, tRF-03357 promotes cell proliferation, migration and invasion, partly by modulating HMBOX1. And this phenomenon can be reversed by targeting tRF-03357 (Zhang et al., 2019a). These functions indicate that tRNAs and tsRNAs can be used as therapeutic targets for clinical interventions.
However, as a therapeutic target, more precise mechanisms of action and higher sensitivity specificity are required, which still leaves some unexplored areas.

CONCLUSION AND PERSPECTIVES

Recent studies have revealed they are key role to various human diseases’ development, especially cancer. Meanwhile, tsRNAs are increasingly being tapped for its potential role in diseases. This review summarizes recent literature on the biogenesis, structure, and biological characteristics and functions of tRNAs and tsRNAs, with an extraordinary attention to their participation and potential clinical significance in human cancers.

In human cancer, tRNAs and tsRNAs possess carcinogenic roles by promoting cell proliferation, migration, and invasion and inhibiting apoptosis (Santos et al., 2019). Meanwhile, tRNAs and tsRNAs also have anti-tumor effects. Although in clinical settings, fluid screening mainly focuses on miRNAs (Hayes et al., 2014; Romaine et al., 2015). However, tRNAs and tsRNAs are stably enriched in the biofluids in solid cancers and blood malignancies, (Zhang et al., 2009; Li et al., 2012), fluid screening can determine tRNAs and tsRNAs biomarker candidates for cancer diagnosis.

Several studies have confirmed that tRNAs and tsRNAs regulate cancer progression. Indeed, such mechanisms may become suitable targets for novel therapeutic approaches in several tumor types. Although tRNA has already been confirmed as a regulator, it remains unclear whether its dysregulation in many cancers is a trigger for tumor initiation, progress, or metastasis.

Compared with that on other non-coding RNAs, i.e., miRNA and lncRNA, the current state of knowledge on tRNAs and tsRNAs are still in its infancy, and they have not yet been studied in clinical settings. There are several challenges and limitations in the study of tRNAs. First, the molecular mechanism of tRNAs and tsRNAs in cancer development needs to be further confirmed. Second, most studies on tRNAs and tsRNAs and their role in cancer used cancer cells. To advance research in this field, future studies should utilize clinical samples, such as tumor tissues and body fluids. Third, how to utilize tRNAs and tsRNAs against cancer cells effectively and with long-term efficacy should be sufficiently addressed. Fourth, to ensure their safety and efficacy in human, pre-clinical and clinical studies are warranted. Lastly, the relationship between mutations in mitochondrial tRNA and maternal genetic diseases needs to be more clearly studied.

In conclusion, this review bridges the gap between what is known about tRNAs and tsRNAs and their involvement in human cancer, thus providing new insights and strategies for cancer diagnosis, management, and treatment (Hopper and Phizicky, 2003).

AUTHOR CONTRIBUTIONS

SX and YL provided direction and guidance throughout the preparation of this manuscript. ZQ wrote and edited the manuscript. QW and LL generated the figures and made significant revisions to the manuscript. GL, YH, SN, LZ, XZ, YC, JW, XW, and SY compiled the related literature. All authors have read and approved the final version of the manuscript.

FUNDING

This work was funded the National Natural Science Foundation of China (grant numbers 82072904, 81872149, 82103325); the Outstanding Youth Project of Heilongjiang Provincial Natural Science Foundation (grant number YQ2019H027); the Distinguished Young Scholars of Harbin Medical University Cancer Hospital (grant number JCQN2018-03) and the Young Elite Training Foundation Grant of Harbin Medical University Cancer Hospital (grant number JY2016-02); Postgraduate Practice Innovation Project of Harbin Medical University (grant number YJSCX2020-120HYD).

REFERENCES

Alvarado-Vásquez, N., Santiago, J., Alcázar-Leyva, S., Zenteno, E., Negrete-García, C., and Alcázar-Montenegro, H. (2005). A Fungal tRNA of Aspergillus niger Induces IPN-Beta Synthesis in HEP-2 Cells. Life Sci. 77, 578–588. doi:10.1016/j.lfs.2004.11.034
Anumath, G., Biswas, G., Zhang, S. Y., Klein-Szanto, A., Vijayasaranthy, C., and Avadhani, N. G. (2001). Mitochondria-to-nucleus Stress Signaling Induces Phenotypic Changes, Tumor Progression and Cell Invasion. EMBO J. 20, 1910–1920. doi:10.1093/emboj/20.8.1910
An, J. X., Ma, Z. S., Ma, M. H., Shao, S., Cao, F. L., and Dai, D. Q. (2019). MiR-1236-3p Serves as a New Diagnostic and Prognostic Biomarker for Gastric Cancer. Cancer Biomark 25, 127–132. doi:10.3233/CBM-171026
Anderson, P., and Ivanov, P. (2014). tRF Fragments in Human Health and Disease. FEBS Lett. 588, 4297–4304. doi:10.1016/j.febslet.2014.09.001
Babiarz, J. E., Ruby, J. G., Wang, Y., Bartel, D. P., and Blelloch, R. (2008). Mouse ES Cells Express Endogenous shRNAs, siRNAs, and Other Microprocessor-independent, Dicer-dependent Small RNAs. Genes Dev. 22, 2773–2785. doi:10.1101/gad.1705308
Chen, Q., Yan, M., Cao, Z., Li, X., Zhang, Y., Shi, J., et al. (2016). Sperm tsRNAs Contribute to Intergenerational Inheritance of an Acquired Metabolic Disorder. *Science* 351, 397–400. doi:10.1126/science.aad7977

Clarke, C. J., Berg, T. J., Birch, J., Ennis, D., Mitchell, L., Cloix, C., et al. (2016). The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis. *Curr. Biol*. 26, 755–765. doi:10.1016/j.cub.2016.01.045

Couvillion, M. T., Bounova, G., Purdom, E., Speed, T. P., and Collins, K. (2012). A Deep Sequencing of Serum Small RNAs Identifies tRNA Halves: The Next Generation of Immune Signaling. *Angiogenin-Induced tRNA Fragments*. doi:10.3390/ncrna5010018

Dhahbi, J. M., Spindler, S. R., Atamna, H., Boffelli, D., and Martin, D. I. (2014). tRNA Halves: The Next Generation of Immune Signaling. doi:10.1038/mt.2015.124

Eichhorn, S. W., Guo, H., Mcgeary, S. E., Rodriguez-Mias, R. A., Shin, C., Baek, D., Delaunay, S., Rapino, F., Tharan, L., Zhou, Z., Heukamp, L., Termath, M., et al. (2014). mRNA Destabilization Is the Dominant Effect of Mammalian tRNA Derivatives. doi:10.1084/jem.20160397

Frye, M., and Watt, F. M. (2006). The RNA Methyltransferase Misu (NSun2) Mediates Myc-Induced Proliferation and Is Upregulated in Tumors. *Curr. Biol*. 16, 971–981. doi:10.1016/cub.2006.04.027

Fu, H., Feng, J., Liu, Q., Sun, F., Tie, Y., Zhu, J., et al. (2009). Stress Induces tRNA Cleavage by Angiogenin in Mammalian Cells. *FEBS Lett*. 585, 437–442. doi:10.1016/j.febslet.2008.12.043

Gebetsberger, J., Wyss, L., Mleczko, A. M., Reuther, J., and Polacek, N. (2017). A tRNA-Derived Fragment Competes with mRNAs for Ribosome Binding and Regulates Translation during Stress. *RNA Biol*. 14, 1364–1373. doi:10.1080/15476286.2016.1257470

Gomez-Roman, N., Grandori, C., Eisenman, R. N., and White, R. J. (2003). Direct Activation of RNA Polymerase III Transcription by C-Myc. *Nature* 421, 290–294. doi:10.1038/nature01327

Goodarzi, H., Liu, X., Nguyen, H. C. B., Zhang, S., Fish, L., and Tavazoie, S. F. (2015). Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via XBY1 Displacement. *Cell* 161, 790–802. doi:10.1016/j.cell.2015.02.053

Goodarzi, H., Nguyen, H. C. B., Zhang, S., Dill, B. D., Molina, H., and Tavazoie, S. F. (2016). Modulated Expression of Specific tRNAs Drives Gene Expression and Cancer Progression. *Cell* 165, 1416–1427. doi:10.1016/j.cell.2016.05.046

Gryzowska-Szatkowska, L., and Sława, B. (2012). Polymorphisms in Genes Encoding M-tRNA in Female Breast Cancer in Poland. *Mitochondrial DNA* 23, 106–111. doi:10.3109/19401736.2012.660925

Guo, Y., Bosomper, A., Mohan, S., Erdogan, B., Ye, F., Vickers, K. C., et al. (2015). Transfer RNA Detection by Small RNA Deep Sequencing and Disease Association with Myelodysplastic Syndromes. *BMJ Genomics* 16, 727. doi:10.1136/bmj.s12864-015-1929-y

Haussecker, D., Huang, Y., Lau, A., Parameswaran, P., Fire, A. Z., and Kay, M. A. (2010). Human tRNA-Derived Small RNAs in the Global Regulation of RNA Silencing. *RNA* 16, 675–695. doi:10.1016/j.rna.2009.12.010

Hayes, J., Peruzzi, P., and Lawler, S. (2014). MicroRNAs in Cancer: Biomarkers, Functions and Therapy. *Trends Mol. Med*. 20, 460–469. doi:10.1016/j.molmed.2014.06.005

He, X., Li, F., Bor, B., Koyano, K., Cen, L., Xiao, X., et al. (2018). Human tRNA-Derived Small RNAs Modulate Host-Oral Microbial Interactions. *J. Dent. Res*. 97, 1226–1234. doi:10.1177/0022034517770605

Honda, S., Loher, P., Shigematsu, M., Palazzo, J. P., Suzuki, R., Imoto, I., et al. (2015). Sex Hormone-dependent tRNA Halves Enhance Cell Proliferation in Breast and Prostate Cancers. *Proc. Natl. Acad. Sci. U S A* 112, E3816–E3825. doi:10.1073/pnas.1500771112

Hopper, A. K., and Phizicky, E. M. (2003). tRNA Transfers to the Limelight. *Genes Dev*. 17, 162–180. doi:10.1101/gad.1049103

Horton, R., Wilming, L., Rand, V., Lovering, R. C., Bruford, E. A., Khodiyar, V. K., et al. (2004). Gene Map of the Extended Human MHC. *Nat. Genet.* 36, 889–899. doi:10.1038/ng10489

Huang, B., Yang, H., Cheng, X., Wang, D., Fu, S., Shen, W., et al. (2017). tRF/miR-1280 Suppresses Stem Cell-like Cells and Metastasis in Colorectal Cancer. *Cancer Res*. 77, 3194–3206. doi:10.1158/0008-5472.CAN-16-3146

Ivanov, P., Emara, M. M., Villen, J., Gygi, S. P., and Anderson, P. (2011). Angiogenin-induced tRNA Fragments Inhibit Translation Initiation. *Mol. Cell* 43, 613–623. doi:10.1016/j.molcel.2011.06.022

Ivanov, P., O’Day, E., Emara, M. M., Wagner, G., Lieberman, J., and Anderson, P. (2014). G-quadruplex Structures Contribute to the Neuroprotective Effects of Angiogenin-induced tRNA Fragments. *Proc. Natl. Acad. Sci. U S A* 111, 18201–18206. doi:10.1073/pnas.1407361111

Jara-Palomares, L., Otero, R., Jiménez, D., Praena-Fernández, J. M., Rivas, A., Font, C., et al. (2018). Sex Differences in Patients with Occult Cancer after Venous Thromboembolism. *Clin. Appl. Thromb. Hemost.* 24, 489–495. doi:10.1177/1076029217711805

Jin, D., and Musier-Forsyth, K. (2019). Role of Host tRNAs and Amiocaucyl-tRNA Synthetases in Retroviral Replication. *J. Biol. Chem.* 294, 5352–5364. doi:10.1074/jbc.V118.002957

Johnson, S. A., Dabeu, L., and Johnson, D. L. (2008). Enhanced RNA Polymerase III-dependent Transcription Is Required for Oncogenic Transformation. *J. Biol. Chem.* 283, 19184–19191. doi:10.1074/jbc.M800277200

Karaiskos, S., Naqvi, A. S., Swanson, K. E., and Grigoriev, A. (2015). Age-driven Modulation of tRNA-Derived Fragments in Drosophila and Their Potential Targets. *BioRxiv* 10, 51. doi:10.1101/036202-015-0081-6

Kearn, S. P., and Hutmagner, G. (2015). tRNA-Derived Fragments (tRFs): Emerging New Roles for an Ancient RNA in the Regulation of Gene Expression. *Life (Basel)* 5, 1638–1651. doi:10.3390/life5041638

Kerr, J., Anderson, C., and Lippman, S. M. (2017). Physical Activity, Sedentary Behaviour, Diet, and Cancer: an Update and Emerging New Evidence. *Lancet Oncol*. 18, e457–e471. doi:10.1016/S1470-2045(17)30411-4

Khattar, E., Kumar, P., Liu, C. Y., Akincilar, S. C., Raju, A., Lakshman, M., et al. (2016). Telomerase Reverse Transcriptase Promotes Cancer Cell Proliferation
Zhang, Y., Zhang, Y., Shi, J., Zhang, H., Cao, Z., Gao, X., et al. (2014). Identification and Characterization of an Ancient Class of Small RNAs Enriched in Serum Associating with Active Infection. *J. Mol. Cel Biol* 6, 172–174. doi:10.1093/jmcb/mjt052

Zhao, C., Tolkach, Y., Schmidt, D., Kristiansen, G., Müller, S. C., and Ellinger, J. (2018). 5′-tRNA Halves Are Dysregulated in Clear Cell Renal Cell Carcinoma. *J. Urol.* 199, 378–383. doi:10.1016/j.juro.2017.07.082

Zhou, J., Liu, S., Chen, Y., Fu, Y., Silver, A. J., Hill, M. S., et al. (2017). Identification of Two Novel Functional tRNA-Derived Fragments Induced in Response to Respiratory Syncytial Virus Infection. *J. Gen. Virol.* 98, 1600–1610. doi:10.1099/jgv.0.000852

Zhou, Y., Goodenbour, J. M., Godley, L. A., Wickrema, A., and Pan, T. (2009). High Levels of tRNA Abundance and Alteration of tRNA Charging by Bortezomib in Multiple Myeloma. *Biochem. Biophys. Res. Commun.* 385, 160–164. doi:10.1016/j.bbrc.2009.05.031

Zhu, L., Li, J., Gong, Y., Wu, Q., Tan, S., Sun, D., et al. (2019). Exosomal tRNA-Derived Small RNA as a Promising Biomarker for Cancer Diagnosis. *Mol. Cancer* 18, 74. doi:10.1186/s12943-019-1000-8

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Qiu, Wang, Liu, Li, Hao, Ning, Zhang, Zhang, Chen, Wu, Wang, Yang, Lin and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.